The suitability of negative pions for radiotherapy: 4 years preclinical research with the biomedical PiE3-beam at SIN.
The radiobiological experiences over 4 years research with the biomedical pion channel of the 590 MeV proton-accelerator of the Swiss Institute for Nuclear Research (SIN) have been summarized. Mainly sensitive biological systems have been chosen (limiting factor: dose-rate not more than 10 rad/min, exceptionally till 30 rad/min). The RBE values in the peak region vary between 0.7-3.3 and in the plateau region between 0.4-1. The gain factors for pion radiotherapy of cancer are, beside the excellent physical dose distribution, irradiation in the same treatment with two types of radiation: sparsely ionizing (low LET) radiation in plateau (healthy tissue) region and densely ionizing (high LET) radiation in peak (tumor) region. The biological effectiveness ratio in peak and plateau as the clinically most important relation vary between 1.4-4.2. This is valid also for clinically limiting factors such as reaction of skin, of small intestine, vascular damage, dominant lethals in hypoxic cells, tumor induction. For peak pions the RBE in hypoxic cells (tumor cells) can be much higher than in euoxic cells (healthy tissue). This preclinical work supports the hope in a highly effective cancer therapy with negative pions.
D000818:Animals; D002478:Cells, Cultured / Q000528:radiation effects; D004601:Elementary Particles; D004735:Energy Transfer; D005799:Genes, Dominant / Q000528:radiation effects; D005804:Genes, Lethal / Q000528:radiation effects; D008297:Male; D009154:Mutation / Q000528:radiation effects; D010100:Oxygen; D011882:Radiotherapy, High-Energy; D012062:Relative Biological Effectiveness; D013090:Spermatocytes / Q000528:radiation effects
D010100:Oxygen